No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Operating both domestically in India and internationally, Laurus Labs Limited, through its various subsidiaries, is a diversified pharmaceutical company engaged in the research, development, manufacturing, and commercialization of both active pharmaceutical ingredients (APIs) and finished drug products. The firm produces APIs and advanced intermediates for a broad spectrum of therapeutic areas, including anti-retroviral (ARV), anti-diabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Complementing this, it also develops and manufactures oral solid formulations addressing ARV, anti-diabetic, cardiovascular, PPI, and central nervous system indications. Laurus Labs extends its expertise to provide contract development and manufacturing (CDMO) services to other pharmaceutical entities. Furthermore, it produces and markets specialized ingredients utilized in nutraceutical, dietary supplement, and cosmeceutical applications. Innovatively, the company is involved in pioneering enzymatic solutions for industrial biotechnology and crafting animal-origin-free recombinant proteins and enzymes for biopharmaceutical use. Business support services for the pharmaceutical sector are another aspect of its operations. Laurus Labs Limited was founded in Hyderabad, India, in 2005.
www.lauruslabs.comNo one on the platform currently holds LAURUSLABS.BO.
No tracked institution reports a position in LAURUSLABS.BO as of their last filing.
No one on the platform has traded LAURUSLABS.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 12.7% | 23.5% | 25.5% | — | — | — |
| Rev. Growth % | 22.7% | 7.2% | ||||
| Profit Margin % | 13.0% | 10.5% | 10.4% | |||
| Free Cash Flow Margin % | 5.7% | 1.1% | 1.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $83.3B | +21.0% | $25.12 | $22.69–$27.49 | — | 10 |
| 2028 | $96.9B | +16.3% | $30.58 | $23.25–$38.36 | — | 13 |
| 2029 | $114.9B | +18.5% | $37.31 | $34.24–$38.57 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-24 | $4.91 | $6.80 | +38.5% |
| 2026-04-30 | $4.97 | $5.20 | +4.6% |
| 2026-01-23 | $3.68 | $4.70 | +27.7% |
| 2025-10-22 | $2.49 | $3.61 | +45.0% |
| 2025-07-23 | $2.12 | $3.02 | +42.5% |
| 2025-04-24 | $3.29 | $4.30 | +30.7% |
| 2025-01-24 | $1.32 | $1.70 | +28.8% |
| 2024-10-24 | $0.91 | $0.37 | -59.3% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| LAURUSLABS.BOLaurus Labs Limited | $1897.75 | -1.31% | $1.02T | — |
| ALKEM.BOAlkem Laboratories Limited | $5152.00 | -0.06% | $615.1B | — |
| ALKEM.NSAlkem Laboratories Limited | $5163.00 | +0.04% | $617.3B | — |
| AUROPHARMA.BOAurobindo Pharma Limited | $1647.90 | -1.02% | $947.8B | — |
| AUROPHARMA.NSAurobindo Pharma Limited |
| $1648.80 |
| -0.67% |
| $948.7B |
| — |
| BIOCON.BOBiocon Limited | $375.60 | -1.42% | $512.1B | — |
| BIOCON.NSBiocon Limited | $375.45 | -1.71% | $512.9B | — |
Source: Financial Modeling Prep · peers by sector/industry